Table 6.
Short-term outcome for antiglycemic treatment based on current glycated hemoglobin A1c (HbA1c)
| Current HbA1c level | Samples, n | Before adjustment | After propensity score weighting adjustment | ||||
|
|
|
Incidence, n (%) | P value | ORb | 95% CI | P value | |
| Low (<7%) |
|
|
<.001 | 1.79 | 1.69-1.89 | <.001 | |
|
|
Concordant | 60,428 | 43,836 (72.54) |
|
|
|
|
|
|
Nonconcordant | 5959 | 4034 (67.7) |
|
|
|
|
| Medium (7-9%) |
|
|
<.001 | 1.76 | 1.69-1.83 | <.001 | |
|
|
Concordant | 14,025 | 3816 (27.21) |
|
|
|
|
|
|
Nonconcordant | 76,423 | 16,365 (21.41) |
|
|
|
|
| High (>9%) |
|
|
<.001 | 1.83 | 1.63-2.05 | <.001 | |
|
|
Concordant | 4217 | 611 (14.49) |
|
|
|
|
|
|
Nonconcordant | 17,437 | 1108 (6.35) |
|
|
|
|
aConfounders considered: age, gender, ethnicity, smoking, duration of diabetes, HbA1c, systolic blood pressure/diastolic blood pressure, low-density lipoprotein cholesterol, triglycerides, BMI, estimated glomerular filtration rate, hypertension, hypercholesterolemia, macrovascular complication, microvascular complication, hypoglycemia history.
bOR: odds ratio.